Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy

Authors: Kenji Ina, Ryuichi Furuta, Takae Kataoka, Satoshi Kayukawa, Takashi Yoshida, Takaya Miwa, Yoshitaka Yamamura, Yuuki Takeuchi

Journal: World Journal of Clinical Oncology

Study Design: Retrospective study

Participants: 68 patients with metastatic or recurrent gastric cancer receiving S-1-based chemotherapy as first-line treatment

Intervention: The patients were divided into two groups:

• Chemotherapy alone group (n = 37)
  
• Chemo-immunotherapy group (n = 31): Received lentinan in addition to S-1-based chemotherapy

Outcome Measures:

• Overall survival (OS)
• Adverse effects
• Granulocyte/lymphocyte (G/L) ratio

Summary: The study aimed to examine whether the administration of lentinan could prolong survival in patients with advanced gastric cancer receiving S-1-based chemotherapy. The results showed that the median overall survival was significantly longer in the chemo-immunotherapy group compared to the chemotherapy alone group (689 days vs. 565 days, P = 0.0406). The G/L ratio in patients who received lentinan was maintained around or below 2, which was significantly lower than that in patients who received chemotherapy alone (P < 0.001). ¹ The study concluded that chemo-immunotherapy with lentinan offers a significant advantage over S-1-based chemotherapy alone in terms of survival in patients with advanced gastric  cancer.